Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertake research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
Frequently asked questions
What sector does Propanc Biopharma, Inc (PPCB) operate in?
Propanc Biopharma, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Propanc Biopharma, Inc (PPCB) current stock price?
As of the latest data, Propanc Biopharma, Inc stock price is $2.40, with a previous close of $2.29. Propanc Biopharma, Inc gained $0.11 in the last trading session, representing a 4.8% increase.
What is Propanc Biopharma, Inc (PPCB) current market capitalization?
Propanc Biopharma, Inc market cap is approximately 23.59 million.
What is Propanc Biopharma, Inc (PPCB) Earnings Per Share (EPS)?
The trailing EPS is -$17.62.
What is Propanc Biopharma, Inc (PPCB) EBITDA?
Propanc Biopharma, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.45 million.
Does Propanc Biopharma, Inc (PPCB) pay dividends?
No. Propanc Biopharma, Inc does not pay a dividend.
When is Propanc Biopharma, Inc (PPCB) next earnings report?
Propanc Biopharma, Inc is expected to release its next earnings report on September 30, 2026.
What is Propanc Biopharma, Inc (PPCB) beta (volatility) score?
Propanc Biopharma, Inc has a beta of 3.332, indicating very high volatility compared to the market.
